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Abstract
The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic
leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy. Here, we present the
case of a 32-year-old male patient with refractory B-precursor ALL who was resistant to treatment with blinatumomab.
Bone marrow immunohistochemistry revealed T cell infiltrates and an increase in programmed death-ligand 1 (PD-L1)-
positive ALL cells as a potential immune escape mechanism. We were able to recapitulate the clinical observation in vitro
by showing that blinatumomab was not able to mediate cytotoxicity of CD19-positive ALL cells using autologous T cells.
In contrast, the addition of healthy donor T cells led to lysis of ALL cells.
These results strongly encourage further systematic evaluation of checkpoint molecules in cases of blinatumomab treatment
failure and might highlight a possible mechanism to overcome resistance to this otherwise highly effective treatment.
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Background
Bispecific T cell engaging (BiTE®) antibody constructs
represent a novel class of therapeutic antibodies, which
are comprised of two single-chain variable fragments
simultaneously binding CD3-positive T cells and a spe-
cific tumor target antigen [1]. Blinatumomab is the first
of BiTE® antibody construct which entered the clinic and
simultaneously binds CD3-positive T cells and CD19-
positive B cells. The design of this BiTE® molecule brings
CD19-positive target cells in close contact with CD3-
positive T cells. Importantly, binding of the BiTE®
molecule results in polyclonal T cell activation and ex-
pansion which results in effective lysis of the target cells
irrespective of T cell specificity [2, 3]. Blinatumomab has
shown to have antileukemic activity in patients with B-
precursor acute lymphoblastic leukemia (ALL) [4], and
recently, blinatumomab was approved for the treatment
of relapsed or refractory B-precursor ALL by the FDA
(http://www.fda.gov/drugs/informationondrugs/appro-
veddrugs/ucm425597.htm). Loss of CD19 and extrame-
dullary relapse have been observed as mechanisms of
resistance to blinatumomab treatment [5, 6]; however,
other mechanisms of resistance have not been reported
so far.
Upregulation of programmed death-ligand 1 (PD-L1)
on tumor cells in response to endogenous anti-tumor
immunity [7] inhibits adaptive immune responses by in-
ducing T cell dysfunction [8]. Expression of PD-L1 on
tumor cells has been associated with poor outcome in
solid cancers [9] as well as hematologic malignancies
[10]. Antibodies targeting PD-L1 as well as its receptor
on T cells, programmed cell death-1 (PD-1), are being
evaluated in a variety of cancers [9, 11, 12], including
lymphoid malignancies [7]. Recently, two antibodies tar-
geting PD-1 were granted approval for the treatment of
advanced melanoma (pembrolizumab, nivolumab) as
well as metastatic squamous non-small cell lung cancer
(nivolumab). Interestingly, activity of these therapies is
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not limited to PD-L1-positive cancers, as clinical re-
sponses could be detected in cases with low PD-L1 ex-
pression [13]. There is extensive research in the field
trying to develop improved predictive biomarkers to
identify those patients which will response to mono- as
well as combination immunotherapies [14].
Case presentation
A 32-year-old male patient presented with refractory B-
precursor ALL after frontline treatment with induction I
and II as well as consolidation I of the German multi-
center study group on adult acute lymphoblastic
leukemia (GMALL) treatment protocol (analogous to
the GMALL trial 07/2003, Clinicaltrials.gov identifier:
00198991). He was subsequently transferred to our cen-
ter and received blinatumomab as a continuous infusion
at a dose of 9 μg/day for 7 days and 28 μg/day for the
subsequent 21 days. Bone marrow blast count prior to
treatment with blinatumomab (baseline) was 30 %
(Fig. 1c, left panel), and lymphoblasts homogenously
Fig. 1 Increase of PD-1 and PD-L1 positivity after treatment with blinatumomab. a CD19 vs. CD34 expression of lymphoblasts detected by flow cytometry.
Lymphoblasts showed homogenous expression of CD19 at baseline (pre-treatment) as well as after blinatumomab treatment (post-treatment).
b Lymphocyte counts on peripheral blood during blinatumomab treatment. Lymphocyte counts decreased during blinatumomab treatment (1596/μl
on day 0, 986/μl on day 7, 464/μl on day 14, 368/μl on day 21, and 217/μl on day 28). c Hematoxylin and eosin stain of paraffin embedded bone marrow
core biopsy showing diffuse infiltration of immature progenitors at both time points (pre-treatment blast count 30 %, post-treatment 60 %).
d Immunohistochemistry of paraffin embedded bone marrow core biopsy stained for CD3 showing spotted infiltration of CD3-positive T cells
at baseline (5–10 %, pre-treatment) and diffuse infiltration after blinatumomab treatment (20–30 %, post-treatment). e Immunohistochemistry
of paraffin embedded bone marrow core biopsy stained for PD-1 showing 5 % PD-1-positive cells at baseline (pre-treatment) vs. 15 % after
blinatumomab treatment (post-treatment). f Immunohistochemistry of paraffin embedded bone marrow core biopsy stained for PD-L1 showing 2 %
PD-L1-positive blasts at baseline (pre-treatment) vs. 40 % after blinatumomab treatment (post-treatment)
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expressed CD19 (Fig. 1a, left panel). Treatment was well
tolerated with pyrexia on days 1 through 4 of blinatumo-
mab treatment being the only adverse event. Examin-
ation of peripheral blood revealed a decrease of total
lymphocyte counts during treatment (1596/μl on day 0 vs.
217/μl on day 28, Fig. 1b) including decreased T cells (960
CD3-positive T cells/μl on day 5 vs. 180/μl on day 28).
Interestingly, there was a moderate increase in CD3-
positive T cells within the bone marrow (5–10 % at base-
line vs. 20–30 % after blinatumomab treatment, Fig. 1d).
Upon completion of the first cycle, bone marrow
examination revealed persistent leukemia with a blast
count of 60 % (Fig. 1c, right panel), showing
homogenous expression of CD19 (Fig. 1a, right panel).
Since a loss of CD19 as the mechanism of resistance
could not be detected, we examined PD-1 and PD-L1
expression in the bone marrow by immunohistochemis-
try. A moderate increase in PD-1 positivity was seen in
lymphocytes in the bone marrow by immunohistochem-
istry (5 % PD-1-positive cells at baseline vs. 15 % after
blinatumomab treatment, Fig. 1e). However, we observed
a marked increase of PD-L1 positivity (2 % PD-L1-
positive blasts at baseline vs. 40 % after blinatumomab
treatment, Fig. 1f ). In contrast to the bone marrow, no
PD-1 expression was observed on T cells from the per-
ipheral blood (Fig. 2a).
Finally, we collected the patient’s peripheral blood after
blinatumomab treatment and purified CD3-positive T cells
(EasySep™ Human CD3 Positive Selection Kit II, Stemcell
Technologies, Vancouver, British Columbia, Canada). Of ei-
ther patient or healthy donor CD3-positive T cells, 2.5 × 105
were cocultured with 5 × 105 of the patient’s ALL cells
(CD3-negative cells) with blinatumomab or control-BiTE®
at a dose of 5 ng/ml on 3 × 104 irradiated MS-5 feeder cells.
After 3 days, cells were stained with CD19-PE, CD2-
BV421, and murine CD29-APC-Cy7 (all BioLegend, San
Diego, CA, USA), as well as LIVE/DEAD® Fixable Aqua
Dead Cell Stain Kit (Life Technologies, Carlsbad, CA,
USA), and analyzed on a LSR II flow cytometer (BD Biosci-
ences, Heidelberg, Germany). After cell counting, the per-
centage of the respective cell population determined by
flow cytometry was used to determine the absolute cell
counts. Percentage of specific lysis was calculated using cell
counts of control-BiTE® antibody-treated relative to
blinatumomab-treated cultures, as described previously
[15]. The interferon-γ (IFN-γ) concentration in cell culture
supernatants was measured by cytometric bead array (BD™
CBA Human IFN-γ Flex Set, BD Biosciences, Heidelberg,
Germany) according to the manufacturer’s instructions on
the same machine.
In vitro, the patient’s T cells showed considerably less
lysis of CD19-positive cells (8.5 vs. 93.6 % for healthy
donor T cells, Fig. 2b, c). This was accompanied by con-
siderably lower concentrations of IFN-γ in cell culture
supernatants (47.7 vs. 2100.9 pg/ml for healthy donor T
cells, Fig. 2d). These results recapitulate the clinical ex-
perience with an inability of the patients’ T cells to per-
form blinatumomab-mediated lysis of ALL cells.
Fig. 2 Decreased in vitro blinatumomab-mediated lysis of ALL blasts by patient CD3-positive T cells. a PD-1 expression on peripheral CD3-positive T
cells was compared to PD-1 expression on healthy donor CD3-positive T cells showing no detectable difference. b The patient’s ALL blasts were cocultured
either with healthy donor CD3-positive T cells (upper panels) or the patient’s own CD3-positive T cells (lower panels) with either control-Bite® (left panels) or
blinatumomab (right panels) and analyzed by flow cytometry after 3 days. c Specific lysis was calculated as one minus the ratio of CD19-positive cells
treated with blinatumomab and CD19-positive cells treated with control-Bite®. Healthy donor CD3-positive T cells showed efficient lysis of our patient’s
ALL blasts (specific lysis 93.6 %) whereas CD3-positive T cells from our patient showed inefficient lysis of autologous ALL blasts (specific lysis 8.5 %).
d IFN-γ concentration in cell culture supernatants were considerably lower for our patient’s T cells cocultured with his ALL blasts, whereas coculture of
healthy donor T cells and ALL blasts from our patient led to considerable IFN-γ production. Cell cultures with control-Bite® did not show
any IFN-γ production
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Discussion and conclusions
Taken together, our data suggests a role of PD-L1 in
treatment resistance to blinatumomab in our patient.
This is, to our knowledge, the first report of increased
PD-L1 positivity in a patient receiving blinatumomab
and should encourage a systematic evaluation of the
relevance of this resistance mechanism in patients re-
ceiving bispecific T cell engager therapy. A large body of
evidence has been suggesting a key role of the PD-1/PD-
L1 axis in attenuating anti-tumor immune responses
[16, 17]. Recently, we described this mechanism of re-
sistance in the context of BiTE® antibody immunother-
apy in vitro [18]. Detecting an increase of PD-L1 in a
patient receiving blinatumomab therefore highlights the
relevance of this mechanism in vivo.
Additionally, several resistance mechanisms to antibody-
based immunotherapy have been reported including vari-
ation of target antigen expression (which might be present
initially or develop during therapy), activation of alternative
signaling pathways, and anti-antibody formation [19–22].
In the context of novel immunotherapies, including blina-
tumomab, assessment of resistance mechanisms is limited
and warrants further investigation. Upregulation of check-
point molecules represents an adaptive resistance to anti-
tumor immunity which we hypothesize will also take place
in other T cell recruiting antibody formats (e.g., DARTS,
diabodies) as well as adoptive T cell therapies (e.g., CAR T
cells, tumor antigen-specific TCR Tcells). It will be import-
ant to conduct close monitoring of biomarkers and careful
consideration of specific time points recognizing the dy-
namic interplay of receptor-ligand interactions. Further
studies are warranted to analyze the significance of the PD-
1/PD-L1 interplay as a resistance mechanism to blinatu-
momab. Ultimately, combinatorial approaches might have
the potential to revert T cell-induced immune escape strat-
egies and avoid treatment failure in these otherwise highly
effective treatments.
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